Corcept Therapeutics

Corcept Therapeutics is a commercial-stage pharmaceutical company that discovers and develops medicines that treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of cortisol, the body's primary stress hormone. Founded in 1998 and based in Redwood City, California, Corcept built its business on Korlym, the first FDA-approved treatment for hypercortisolism (Cushing's syndrome), and has since discovered more than 1,000 proprietary selective cortisol modulators. In 2026 it won FDA approval for Lifyorli (relacorilant) in platinum-resistant ovarian cancer, extending a single scientific idea - blocking cortisol at the glucocorticoid receptor - from a rare endocrine disease into oncology.